NuCana PLC（NCNA）股票分析

AI 分析 of NuCana PLC (NCNA)

卖出

NuCana PLC (NCNA) is not a good buy right now due to its significant financial losses and poor technical indicators. The stock has a current price of $0.94, which is close to its 52-week low of $0.90, indicating a lack of upward momentum. Additionally, the RSI is at 32.144, suggesting that the stock is oversold, but this could also indicate ongoing weakness rather than an imminent recovery. The company has reported a staggering year-to-date change of -74.24%, reflecting severe challenges in its financial performance, including a gross profit of £0.00 in recent quarters and a forward P/E ratio of 0, which indicates no expected earnings growth. The main risk is the continued negative net income, with the latest reported loss of £3.08 million in Q2 2026, which raises concerns about the company's viability moving forward.

分析师评级（4）

买入

4 买入

0 持有

0 卖出

当前: 0.94

最低

—

平均

—

最高

—

Oppenheimer

买入

$25

2024-09-03

Oppenheimer

2024-09-03

目标价

$25

买入

William Blair

持有

—

2024-08-30

William Blair

2024-08-30

目标价

—

持有

Oppenheimer

买入

$150

2024-08-19

Oppenheimer

2024-08-19

目标价

$150

买入

Oppenheimer

买入

$150

2024-07-23

Oppenheimer

2024-07-23

目标价

$150

买入

Oppenheimer

买入

$150

2024-07-22

Oppenheimer

2024-07-22

目标价

$150

买入

查看全部评级

估值指标

NuCana PLC（NCNA）当前预期市盈率为 0.00，5 年平均预期市盈率为 -12.95。

预期市盈率

合理

5 年均值 P/E

-12.95

当前P/E

0.00

高估

20.32

低估

-46.23

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-0.02

当前EV/EBITDA

0.00

高估

0.45

低估

-0.50

预期市销率

合理

5 年均值 P/S

2.72

当前P/S

0.00

高估

13.71

低估

-8.27

Alphio AI 对 NCNA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%NCNA

$0.06

情景价格

基

基准

基准 · 50%NCNA

$0.05

情景价格

悲

悲观

悲观 · 25%NCNA

$0.05

情景价格

NCNA 常见问题 —— 由 Alphio AI 解答

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NuCana PLC (NCNA) is not a good buy right now due to its significant financial losses and poor technical indicators. The stock has a current price of $0.94, which is close to its 52-week low of $0.90, indicating a lack of upward momentum. Additionally, the RSI is at 32.144, suggesting that the stock is oversold, but this could also indicate ongoing weakness rather than an imminent recovery. The company has reported a staggering year-to-date change of -74.24%, reflecting severe challenges in its financial performance, including a gross profit of £0.00 in recent quarters and a forward P/E ratio of 0, which indicates no expected earnings growth. The main risk is the continued negative net income, with the latest reported loss of £3.08 million in Q2 2026, which raises concerns about the company's viability moving forward.

4 analysts cover NCNA: 4 rate it Buy, 0 Hold and 0 Sell.